Restricted accessResearch articleFirst published online 2020-11
Genetic Variants and Haplotypes in OPG Gene Are Associated with Premature Coronary Artery Disease and Traditional Cardiovascular Risk Factors in Mexican Population: The GEA Study
Basic and clinical research have demonstrated that osteoprotegerin (OPG) plays an important role in the development and progression of cardiovascular diseases. The aim of this study was to evaluate the association of four polymorphic sites (rs2073618, rs3134069, rs3134070, and rs3102735) of OPG gene with premature coronary artery disease (pCAD), and with cardiometabolic parameters. The polymorphisms were genotyped using 5′ exonuclease TaqMan genotyping assays with real-time PCR in 1098 individuals with pCAD and 1041 healthy controls. rs2073618 polymorphism was associated with a high risk of developing pCAD according to different inheritance models: additive (p = 0.001; odds ratio [OR] = 1.283), dominant (p = 0.006; OR = 1.383), recessive (p = 0.011; OR = 1.423), and codominant 2 (p = 0.001; OR = 1.646). The four polymorphisms were associated with different cardiovascular risk factors in individuals with pCAD and controls. Our results suggest that OPG rs2073618 polymorphism is associated with an increased risk of pCAD. In addition, two haplotypes were associated with pCAD, one increasing the risk (CACT) and another one as protective (GACC).
Get full access to this article
View all access options for this article.
References
1.
BreaA., Hernández-MijaresA., MillánJ., AscasoJ.F., BlascoM., DíazA., et al. (2019). Non-HDL cholesterol as a therapeutic goal. Clin Investig Arterioscler, 31 Suppl 2, 28–33.
2.
CarthariusK., FrechK., GroteK., KlockeB., HaltmeierM., KlingenhoffA., et al. (2005). MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics (Oxford, England), 21, 2933–2942.
3.
ChangY., RyuS., SungK.C., ChoY.K., SungE., KimH.N., et al. (2019). Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. Gut, 68, 1667–1675.
4.
ChenB., DuZ., DongX., LiZ., WangQ., ChenG., et al. (2019). Association of variant interactions in RANK, RANKL, OPG, TRAF6, and NFATC1 genes with the development of osteonecrosis of the femoral head. DNA Cell Biol, 38, 734–746.
5.
ChungH.S., LeeJ.S., KimJ.A., RohE., LeeY.B., HongS.H., et al. (2019). γ-glutamyltransferase variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based cohort study. J Clin Med 8,832.
6.
CicconeM.M., ScicchitanoP., GesualdoM., ZitoA., CarbonaraR., LocorotondoM., et al. (2013). Serum osteoprotegerin and carotid intima-media thickness in acute/chronic coronary artery diseases. J Cardiovasc Med (Hagerstown, Md), 14, 43–48.
7.
ClementeA., TraghellaI., MazzoneA., SbranaS., and VassalleC. (2020). Vascular and valvular calcification biomarkers. Adv Clin Chem, 95, 73–103.
8.
EhrlichK.C., and EhrlichM. (1990). Highly repeated sites in the apolipoprotein(a) gene recognized by methylated DNA-binding protein, a sequence-specific DNA-binding protein. Mol Cell Biol, 10, 4957–4960.
9.
FaggianoP., DasseniN., GaibazziN., RossiA., HeneinM., and PressmanG. (2019). Cardiac calcification as a marker of subclinical atherosclerosis and predictor of cardiovascular events: a review of the evidence. Eur J Prev Cardiol, 26, 1191–1204.
10.
FerraraD., MontecuccoF., DallegriF., and CarboneF. (2019). Impact of different ectopic fat depots on cardiovascular and metabolic diseases. J Cell Physiol, 234, 21630–21641.
11.
FordeH., DavenportC., HarperE., CumminsP., and SmithD. (2018). The role of OPG/RANKL in the pathogenesis of diabetic cardiovascular disease. Cardiovasc Endocrinol Metabol, 7, 28–33.
12.
FraynK.N., and CoppackS.W. (1992). Insulin resistance, adipose tissue and coronary heart disease. Clin Sci (London, England: 1979), 82, 1–8.
13.
GreenlandP., BlahaM.J., BudoffM.J., ErbelR., and WatsonK.E. (2018). Coronary calcium score and cardiovascular risk. J Am Coll Cardiol, 72, 434–447.
14.
HakimiM., Hyhlik-DürrA., von AuA., BetzM., DemirelS., DihlmannS., et al. (2013). The expression of glycophorin A and osteoprotegerin is locally increased in carotid atherosclerotic lesions of symptomatic compared to asymptomatic patients. Int J Mol Med, 32, 331–338.
15.
HouY.C., LuC.L., YuanT.H., LiaoM.T., ChaoC.T., and LuK.C. (2020). The epigenetic landscape of vascular calcification: an integrative perspective. Int J Mol Sci 21,980.
16.
JeonJ., KimD.H., KimW., ChoiD.W., JungK.J., and JangS.I. (2020). Dose-response relationship between gamma-glutamyltransferase and the risk of atherosclerotic cardiovascular diseases in Korean adults. Atherosclerosis, 292, 152–159.
17.
JiaP., WuN., JiaD., and SunY. (2017). Association between osteoprotegerin gene polymorphisms and risk of coronary artery disease: a systematic review and meta-analysis. Balkan J Med Genet, 20, 27–34.
18.
Juárez-CedilloT., ZuñigaJ., Acuña-AlonzoV., Pérez-HernándezN., Rodríguez-PérezJ.M., BarqueraR., et al. (2008). Genetic admixture and diversity estimations in the Mexican Mestizo population from Mexico City using 15 STR polymorphic markers. Forensic Sci Int Genet, 2, e37–e39.
19.
KelishadiR., QorbaniM., HeshmatR., Motamed-GorjiN., MotlaghM.E., ZiaodiniH., et al. (2018). Association of alanine aminotransferase concentration with cardiometabolic risk factors in children and adolescents: the CASPIAN-V cross-sectional study. Sao Paulo Med J, 136, 511–519.
20.
KosmopoulosM., PaschouS.A., GrapsaJ., AnagnostisP., VryonidouA., GoulisD.G., et al. (2019). The emerging role of bone markers in diagnosis and risk stratification of patients with coronary artery disease. Angiology, 70, 690–700.
LinJ.F., WuS., JuangJ.J., ChiangF.T., HsuL.A., TengM.S., et al. (2019). Osteoprotegerin and osteopontin levels, but not gene polymorphisms, predict mortality in cardiovascular diseases. Biomarkers Med, 13, 751–760.
23.
LiskerR., RamírezE., and BabinskyV. (1996). Genetic structure of autochthonous populations of Meso-America: Mexico. Hum Biol, 68, 395–404.
24.
LøgstrupB.B., HøfstenD.E., ChristophersenT.B., MøllerJ.E., BjerreM., FlyvbjergA., et al. (2013). Microvascular dysfunction is associated with plasma osteoprotegerin levels in patients with acute myocardial infarction. Coronary Artery Dis, 24, 487–492.
25.
LuoZ.R., and XieQ.J. (2012). [Correlation between osteoprotegerin gene 209G/A, 245T/G and 1181G/C polymorphism and acute coronary syndromes in Han people of Fujian area]. Chin Crit Care Med, 24, 730–733.
26.
MaL.N., DuR., ChengD., LinL., WuX.Y., HuC.Y., et al. (2019). Serum alanine aminotransferase is associated with metabolic syndrome and 10-year risk of cardiovascular disease. Biomed Environ Sci, 32, 121–125.
27.
MakarovićS., MakarovićZ., SteinerR., MihaljevićI., and Milas-AhićJ. (2015). Osteoprotegerin and vascular calcification: clinical and prognostic relevance. Coll Antropol, 39, 461–468.
28.
Mankoč RamušS., KumšeT., Globočnik PetrovičM., PetrovičD., and CilenšekI. (2013). SNP rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes. Biomed Res Int 2013,364073.
29.
MassonW., LoboM., SiniawskiD., MolineroG., HuerínM., and NogueiraJ.P. (2019). Impact of lipid-lowering therapy on mortality according to the baseline non-HDL cholesterol level: a meta-analysis. High Blood Pressure Cardiovasc Prev, 26, 263–272.
30.
MautnerG.C., MautnerS.L., FroehlichJ., FeuersteinI.M., ProschanM.A., RobertsW.C., et al. (1994). Coronary artery calcification: assessment with electron beam CT and histomorphometric correlation. Radiology, 192, 619–623.
31.
Medina-UrrutiaA., Posadas-RomeroC., Posadas-SánchezR., Jorge-GalarzaE., Villarreal-MolinaT., González-Salazar MdelC., et al. (2015). Role of adiponectin and free fatty acids on the association between abdominal visceral fat and insulin resistance. Cardiovasc Diabetol 14,20.
32.
MorisawaT., NakagomiA., KohashiK., KosugiM., KusamaY., AtarashiH., et al. (2015). Osteoprotegerin is associated with endothelial function and predicts early carotid atherosclerosis in patients with coronary artery disease. Int Heart J, 56, 605–612.
33.
Mrozikiewicz-RakowskaB., NehringP., SzymańskiK., Sobczyk-KopciołA., PłoskiR., DrygasW., et al. (2018). Selected RANKL/RANK/OPG system genetic variants in diabetic foot patients. J Diabet Metabol Disord, 17, 287–296.
34.
NdrepepaG., ColleranR., and KastratiA. (2018). Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. Clin Chim Acta, 476, 130–138.
35.
NittaK., AkibaT., UchidaK., OtsuboS., TakeiT., YumuraW., et al. (2004). Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant, 19, 1886–1889.
36.
OhP.C., LeeK., KimT.H., MoonJ., ParkH.W., JangH.J., et al. (2017). Prognostic impact of alkaline phosphatase measured at time of presentation in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. PLoS One 12,e0171914.
37.
OoiE.M., EllisK.L., BarrettPHR, WattsG.F., HungJ., BeilbyJ.P., et al. (2018). Lipoprotein(a) and apolipoprotein(a) isoform size: associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque. Atherosclerosis, 275, 232–238.
38.
OvchinnikovaO.A., FolkersenL., PerssonJ., LindemanJ.H., UelandT., AukrustP., et al. (2014). The collagen cross-linking enzyme lysyl oxidase is associated with the healing of human atherosclerotic lesions. J Int Med, 276, 525–536.
39.
PanhL., RuidavetsJ.B., RousseauH., PetermannA., BongardV., BérardE., et al. (2017). Association between serum alkaline phosphatase and coronary artery calcification in a sample of primary cardiovascular prevention patients. Atherosclerosis, 260, 81–86.
40.
PeteanIBF, KüchlerE.C., SoaresI.M.V., SegatoR.A.B., SilvaL., AntunesL.A.A., et al. (2019). Genetic polymorphisms in RANK and RANKL are associated with persistent apical periodontitis. J Endodontics, 45, 526–531.
41.
PolonskayaY.V., KashtanovaE.V., MurashovI.S., VolkovA.M., KurguzovA.V., ChernyavskyA.M., et al. (2017). Associations of osteocalcin, osteoprotegerin, and calcitonin with inflammation biomarkers in atherosclerotic plaques of coronary arteries. Bullet Exp Biol Med, 162, 726–729.
42.
Posadas-SánchezR., López-Uribe ÁR, Posadas-RomeroC., Pérez-HernándezN., Rodríguez-PérezJ.M., Ocampo-ArcosW.A., et al. (2017a). Association of the I148M/PNPLA3 (rs738409) polymorphism with premature coronary artery disease, fatty liver, and insulin resistance in type 2 diabetic patients and healthy controls. The GEA study. Immunobiology, 222, 960–966.
43.
Posadas-SánchezR., Pérez-HernándezN., Angeles-MartínezJ., López-BautistaF., Villarreal-MolinaT., Rodríguez-PérezJ.M., et al. (2017b). Interleukin 35 polymorphisms are associated with decreased risk of premature coronary artery disease, metabolic parameters, and IL-35 levels: the genetics of atherosclerotic disease (GEA) study. Mediators Inflam 2017,6012795.
44.
RahmaniJ., MiriA., NamjooI., ZamaninourN., MaljaeiM.B., ZhouK., et al. (2019). Elevated liver enzymes and cardiovascular mortality: a systematic review and dose-response meta-analysis of more than one million participants. Eur J Gastroenterol Hepatol, 31, 555–562.
45.
RheeE.J., OhK.W., JungC.H., LeeW.Y., OhE.S., YunE.J., et al. (2006). The relationship between four single nucleotide polymorphisms in the promoter region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans. Clin Endocrinol, 64, 689–697.
46.
SabbahN., JaissonS., GarnotelR., Anglés-CanoE., and GilleryP. (2019). Small size apolipoprotein(a) isoforms enhance inflammatory and proteolytic potential of collagen-primed monocytes. Lipids Health Dis 18,166.
47.
SandbergW.J., YndestadA., ØieE., SmithC., UelandT., OvchinnikovaO., et al. (2006). Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol, 26, 857–863.
48.
SaoR., and AronowW.S. (2018). Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch Med Sci, 14, 1233–1244.
49.
SharmaR.K., SharmaR.K., VoelkerD.J., SinghV.N., PahujaD., NashT., et al. (2010). Cardiac risk stratification: role of the coronary calcium score. Vasc Health Risk Manage, 6, 603–611.
50.
ShengX., CaiG., GongX., YaoZ., and ZhuY. (2017). Common variants in OPG confer risk to bone mineral density variation and osteoporosis fractures. Sci Reports 7,1739.
51.
SiasosG., OikonomouE., ManiatisK., GeorgiopoulosG., KokkouE., TsigkouV., et al. (2018). Prognostic significance of arterial stiffness and osteoprotegerin in patients with stable coronary artery disease. Eur J Clin Invest 48,e12890.
52.
SimonetW.S., LaceyD.L., DunstanC.R., KelleyM., ChangM.S., LüthyR., et al. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89, 309–319.
53.
SinnD.H., KangD., ChangY., RyuS., GuS., KimH., et al. (2017). Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut, 66, 323–329.
54.
SoufiM., SchoppetM., SattlerA.M., HerzumM., MaischB., HofbauerL.C., et al. (2004). Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metabol, 89, 3764–3768.
55.
TmoyanN.A., EzhovM.V., AfanasievaO.I., KlesarevaE.A., RazovaO.A., KukharchukV.V., et al. (2018). The association of lipoprotein(a) and apolipoprotein(a) phenotypes with peripheral artery disease. Terapevticheskii Arkhiv, 90, 31–36.
56.
TousoulisD., SiasosG., ManiatisK., OikonomouE., KioufisS., ZaromitidouM., et al. (2013). Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol, 167, 1924–1928.
57.
UluçayS., ÇamF.S., BatırM.B., SütçüR., Bayturan, Ö., and DemircanK. (2015). A novel association between TGFb1 and ADAMTS4 in coronary artery disease: a new potential mechanism in the progression of atherosclerosis and diabetes. Anatol J Cardiol, 15, 823–829.
58.
WangM., and WanJ. (2019). Soluble regulators of Interleukin-1 signaling: novel biomarkers for early acute myocardial infarction diagnosis and to predict ischemia/reperfusion injury?. Int J Cardiol 274,357.
59.
Wójcik-CichyK., Koślińska-BerkanE., and PiekarskaA. (2018). The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. Clin Exp Hepat, 4, 1–6.
60.
WuF., ZhouD., ShenG., CuiY., LvQ., and WeiF. (2019). Association of VDR and OPG gene polymorphism with osteoporosis risk in Chinese postmenopausal women. Climacteric, 22, 208–212.
61.
WuM., RementerC., and GiachelliC.M. (2013). Vascular calcification: an update on mechanisms and challenges in treatment. Calcified Tissue Int, 93, 365–373.
62.
YangH., LiuW., ZhouX., RuiH., ZhangH., and LiuR. (2019). The association between RANK, RANKL and OPG gene polymorphisms and the risk of rheumatoid arthritis: a case-controlled study and meta-analysis. Biosci Rep 39,BSR20182356.
63.
YasudaH., ShimaN., NakagawaN., MochizukiS.I., YanoK., FujiseN., et al. (1998). Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology, 139, 1329–1337.
64.
ZengL., XiaoQ., ChenM., MargaritiA., MartinD., IveticA., et al. (2013). Vascular endothelial cell growth-activated XBP1 splicing in endothelial cells is crucial for angiogenesis. Circulation, 127, 1712–1722.
65.
ZengL., ZampetakiA., MargaritiA., PepeA.E., AlamS., MartinD., et al. (2009). Sustained activation of XBP1 splicing leads to endothelial apoptosis and atherosclerosis development in response to disturbed flow. Proc Natl Acad Sci U S A, 106, 8326–8331.
66.
ZhaoH.Y., LiuJ.M., NingG., ZhaoY.J., ZhangL.Z., SunL.H., et al. (2005). The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. Osteoporosis Int, 16, 1519–1524.
67.
ZieglerS., KudlacekS., LugerA., and MinarE. (2005). Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis, 182, 175–180.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
